Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration
Expected regulatory pathway for episodic treatment of major depression remains unchanged with plan for one new additional efficacy study Pursuing two additional pathways with the goal of accelerating patient access to zuranolone while continuing development for the episodic treatment of depression
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on March 2, 2020 , the Compensation
View HTML
Toggle Summary Sage Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline and Business Progress
ZULRESSO™ (brexanolone) CIV injection net revenues of $2M and $4M for fourth quarter and full year 2019, respectively Evaluating path forward for the zuranolone (SAGE-217) Landscape Program Continued expansion of Neurology and Neuropsychiatry franchises with planned initiation of additional
View HTML
Toggle Summary Sage Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2020-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at
View HTML
Toggle Summary Sage Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 10, 2020-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 4, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on Monday, February 3,
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on Thursday, January 2,
View HTML
Toggle Summary Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Monday, January 13, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 23, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at
View HTML
Toggle Summary Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
Three poster presentations highlight the role of NMDA receptor dysfunction in Huntington’s Disease related cognitive impairment and potential for positive cognitive effects with SAGE-718 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 10, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical
View HTML
Toggle Summary Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
MOUNTAIN Study did not meet primary endpoint at Day 15 Statistical significance on HAM-D scale achieved at Days 3, 8 and 12; preliminary data from long-term follow-up suggest maintenance of effect on depressive symptoms Statistical significance achieved at Days 3, 8, 12 and 15 in patients with
View HTML